A Phase 2, Randomized, Double-blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of Various Doses and Regimens of EXC 001 for the Amelioration of Scarring Following Revision of Scars From Prior Breast Surgery in Adult Subjects (LEGACY EXCALIARD PROTOCOL # EXC 001-204)
Latest Information Update: 13 Sep 2021
At a glance
- Drugs PF 6473871 (Primary)
- Indications Scars
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 09 May 2014 New trial record